Trial Profile
PembRolIzuMab and Stereotactic Body Radiotherapy In Metastatic Non-small-cell lunG Cancer Patients
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 13 Sep 2022
Price :
$35
*
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Acronyms PRIMING
- 07 Sep 2022 Status changed from active, no longer recruiting to discontinued.
- 11 Jun 2019 Status changed from recruiting to active, no longer recruiting.
- 13 Sep 2018 Status changed from not yet recruiting to recruiting.